Research Towards a LongerActing FactorVIII - PowerPoint PPT Presentation

1 / 22
About This Presentation
Title:

Research Towards a LongerActing FactorVIII

Description:

Research Towards a. Longer-Acting Factor VIII. Bruce M. Ewenstein, MD, PhD ... Baxter is developing 4 approaches for half-life extension ... – PowerPoint PPT presentation

Number of Views:27
Avg rating:3.0/5.0
Slides: 23
Provided by: briangal
Category:

less

Transcript and Presenter's Notes

Title: Research Towards a LongerActing FactorVIII


1
Research Towards aLonger-Acting Factor VIII
CURE
Convenience
t1/2 Improvement
Optimal Therapy
Bruce M. Ewenstein, MD, PhD Global Medical
Director Baxter BioScience
  • Prophylaxis

Pathogen Safety
  • Plasma-Albumin Free Method

2
Molecular Mechanism of FVIII Clearance
Ananyeva et al., 2001 Saenko EL and Ananyeva NM,
2006
3
Potential Targets for FVIIIHalf-Life Extension
  • Indirect modifications
  • Interference with FVIII receptor mediated
    clearance
  • Formulations with improved stability
  • PEGylated liposomes
  • Modification of VWF as the FVIII carrier protein
  • VWF mutant
  • Biochemical modificationof VWF
  • Direct modifications
  • FVIII Mutants
  • Resistant to degradation
  • Resistant to inactivation
  • Resistant to clearance
  • Biochemical modification of FVIII
  • PEGylation
  • Modifications of glycosylation

4
Concepts for a Next-Generation Hemophilia A
Therapy With Improved Pharmacokinetics
  • Baxter is developing 4 approaches for half-life
    extension of Factor VIII (FVIII), pursuing both
    direct and indirect modification

TARGET
APPROACH
rVWF recombinant von Willebrands factor.
5
PEGylationDerivatization of Proteins With
Synthetic Polyethylene Glycol
  • Knowns
  • Enhanced solubility
  • Decreased proteolysis
  • Altered distribution and absorption
  • Enhanced storage stability
  • Increased half-life
  • Unknowns
  • Clearance mechanism of large PEG-protein
    conjugates
  • Effects of long-term exposure
  • Impact on immunogenicity

mPEG2-SBA (Succinimidyl butyrate)
6
PEGylated rFVIII Showed ImprovedPK Parameters
Compared With rFVIII Half-life Increased 2-fold
PEGylated rFVIII In Vivo Evaluation in
FVIII-Deficient Mice
Application of PEG-rFVIII or rFVIII (200 IU
FVIII/kg)
10.00
PEG-rFVIII (200 U/kg)
rFVIII (200 U/kg)
AUC (mUhr/mL)/(mU/kg)
1.00
FVIII (IU/mL) SD
126
65
0.10
n5
0.01
0
10
20
30
Hours Post-infusion
Calculation with MS Excel. AUC area under the
curve.
7
VWF as a Target for the Prolongation of the
Half-Life of FVIII
  • The survival of FVIII in the circulation is
    dependent on its chaperone VWF
  • VWF rapidly forms a tight complex with FVIII with
    high affinity
  • FVIII-VWF complex formation may prevent FVIII
    from interacting with lower affinity binding
    partners, such as FIXa, phospholipids and LRP
  • FVIII bound to VWF is protected from enzymatic
    (in)activation
  • Correlation between pre-infusion from VWF levels
    andhalf-life of FVIII in severe hemophilia A1,2

1. Fijnvandraat et al., Br J Haematol.
199591474-6. 2. Vloet et al., Thromb
Haemost. 200078365-9.
8
rVWF Largest Protein Ever Successfully PEGylated
VWF multimer
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
PEGylation
PEGylated VWF multimer
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
-S-S-
Immunoblot withanti-PEG pAb
Coomassie staining
kDa
  • SDS-PAGE (reduced)
  • Increase in MW
  • after PEGylation
  • Multimer distribution
  • (2.5 agarose)
  • Broadening of all multimer bands in
    PEGylated rVWF

MW marker
MW marker
PEG-rVWF 5K
Native rVWF
Native rVWF
PEG-rVWF 5K
PEG-rVWF 20K
PEG-rVWF 20K
9
Substantial Half-life Increase for rVWF After
PEGylation
PEG-rVWF in FVIII-deficient KO mice
10
PEG-rVWF Demonstrated Substantial Half-life
Increase of FVIII
PEG-rVWF in FVIII-Deficient KO Mice
Dose (200/300 U/kg)
PEG-rVWF / rFVIII
100.0
rVWF / rFVIII
AUC 102
10.0
FVIII ( from Umax)
1.0
AUC 40
n5
0.1
0
5
10
15
20
25
30
35
Hours Post-infusion
(mUh/mL)/(mU/kg).
11
Polysialic Acid (PSA) Technology as an
Alternative to PEGylation
  • Features of PSA
  • ?-2,8-linked polysialic acid
  • Negatively chargedhydrophilic polymer
  • Natural constituent of human tissue
  • Non-immunogenic
  • Biodegradable (to sialic acid)
  • Chemical derivatization of proteins with PSA
  • Preferred process conjugation with Lys residues
    by reductive amination

12
Polysialylation Prolonged VWFHalf-life and
Sustained the Secondary Rise of FVIII
rVWF-polysialic acid conjugate PK in VWD mice
PSA-rVWF (80 IU VWFAg/kg)
rVWF (70 IU VWFAg/kg)
rVWF-PSA
rVWF-PSA
10.0
0.6
rVWF
rVWF
AUC 66
1.0
0.4
AUC 68
VWFAg (U/mL)
FVIII (U/mL)
0.2
0.1
AUC 47
AUC 50
FVIII base level in VWD mice
0.0
0.0
0
5
10
15
20
25
0
5
10
15
20
25
Hours Post-infusion
Hours Post-infusion
(mUh/mL)/(mU/kg). VWD von Willebrand disease.
13
Factor VIII Levels and Bleeding
  • Patients with severe hemophilia A
  • N 64 (51 HA, 13 HB)
  • Individual PKs defined
  • Time FVIII lt1 IU/dL calculated
  • Comparison made with joint bleeds over 6 years
  • For each additional hour per week FVIII lt1, 1.9
    increase in annual hemarthroses

Ahnstrom et al.,Haemophilia 200410689-97
14
Clinical Implications
  • Modeled data from completed ADVATE clinical
    studies
  • For each additional hour per week with FVIII lt1,
    annual bleed rate increased

15
Open Questions
  • Is chemical modification of very large proteins
    feasible, reproducible, and scalable?
  • Is modified rVWF susceptible to specific
    proteolytic degradation by ADAMTS13?
  • Do modified rFVIII and rVWF retain their
    efficacy in vivo?
  • Does PEGylation impact the immunogenicity of rVWF
    and rFVIII?

16
Immunogenicity of PEG-FVIII and FVIII in New
Hemophilia Model
17
Recombinate Expansion
18
Recombinate Expansion
1992 - 1996
19
Recombinate Expansion
1992 - 1996
1997 - 2001
20
Recombinate Expansion
1992 - 1996
1997 - 2001
2001 - 2007
21
Recombinate Expansion
1992 - 1996
1997 - 2001
2001 - 2007
Pending/In Process Registrations
22
Acknowledgments
  • The Half-life Scientific and Technical Team
  • Peter Turecek
  • Hans Peter Schwarz
  • Birgit Reipert
  • Eva Maria Muchitsch
  • Bernhard Baumgartner
  • Herbert Gritsch
  • Katalin Varàdi
  • Fritz Scheiflinger
  • Wolfgang Mundt
  • Artur Mitterer
  • Hartmut Ehrlich
  • gt150 Team members of Baxter RD currently working
    on our hemophilia project
Write a Comment
User Comments (0)
About PowerShow.com